// App-Quantinova.ai

374.0 : An analysis of the safety and efficacy of rivaroxaban (Riv) and low molecular weight heparin (LMWH) in gastrointestinal cancer-associated venous thromboembolism (GICA-VTE).

Researchers

Presenter

  • Alejandro Recio Boiles

Principal Investigators

  • Sumana Veeravelli

  • Jessi Vondrak

  • Hani M. Babiker

  • Aaron James Scott

  • Ali McBride

  • Emad Elquza

Medical Centers

  • University of Arizona Cancer Center, Tucson, AZ

  • University of Arizona College of Medicine Tuscon, Tuscon, AZ

  • University of Arizona Department of Economics, Tucson, AZ

  • Banner-University of Arizona Cancer Center, Division of Hematology and Oncology, Tucson, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Gastric Cancer

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved